

Re: Your request made under the Freedom of Information Act 2000

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from January to April 2022:

- Aflibercept - 1093
- Bevacizumab - 13
- Brolucizumab - 1
- Dexamethasone - 7
- Fluocinolone acetonide - 0
- Ranibizumab - 29

2. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2022.

We cannot answer this question we do not record indication/diagnosis data on the pharmacy system

Number of Injections/Implants: Jan to Apr 2022

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration wAMD	Diabetic Macular Degeneration DMO	Retinal Vein Occlusion RVO
Aflibercept			
Bevacizumab			
Brolucizumab			
Dexamethasone			
Fluocinolone acetonide			
Ranibizumab			

There is clinically no clinical coding or reconciliation that is able to distinguish between wet and dry macular degeneration. Therefore, the Trust is unable to respond to this question.